Angiogenesis inhibitors.

被引：13

作者：

Tennant T.R. ^{[1
]}

Rinker-Schaeffer C.W. ^{[1
]}

Stadler W.M. ^{[1
]}

机构：

[1] Section of Hematology/Oncology, University of Chicago, 5841 South Maryland, Chicago, 60637, IL

来源：

Current Oncology Reports | 2000年 / 2卷 / 1期

关键词：

Vascular Endothelial Growth Factor; Thalidomide; Angiogenesis Inhibitor; Clinical Trial Design; SU5416;

D O I：

10.1007/s11912-000-0005-0

中图分类号：

学科分类号：

摘要：

Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block angiogenesis activators; 4) drugs that inhibit endothelial cell integrins or survival signaling; and 5) drugs with a currently unknown mechanism of action. The properties of these drugs and some specific agents in each class are reviewed in this article. Because growth inhibition rather than tumor shrinkage is expected to be the clinical effect of angiogenesis inhibitors, some of the challenges and potential solutions for clinical trial design are also discussed.

引用

页码：11 / 16

页数：5

共 50 条

[1] Early development of angiogenesis inhibitors.
Harris, AL
CLINICAL CANCER RESEARCH, 1999, 5 : 3876S - 3876S
[2] Design and preparation of novel angiogenesis inhibitors.
Steuer, A
Robinson, TP
Ehlers, T
Arbiser, JL
Goldsmith, D
Bowen, JP
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U405 - U405
[3] Angiogenesis inhibitors. New anticancer strategy
Zgodzinski, W
Wallner, G
Dabrowski, A
POLISH JOURNAL OF PHARMACOLOGY, 1999, 51 (06): : 455 - 462
[4] Angiogenesis inhibitors. Drug selectivity and target specificity
Kesisis, Georgios
Broxterman, Henk
Giaccone, Giuseppe
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (27) : 2795 - 2809
[5] Design, synthesis, and biological evaluation of novel angiogenesis inhibitors.
Bowen, JP
Furness, S
Robinson, TP
Ehlers, T
Arbiser, JL
Goldsmith, D
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : U465 - U465
[6] Respiratory inhibitors.
Dixon, M
ARCHIV FUR EXPERIMENTELLE ZELLFORSCHUNG, 1934, 15 : 17 - 26
[7] Silanediol metalloprotease inhibitors. Synthesis and evaluation of four ace inhibitors.
Kim, J
Hewitt, GW
Mutahi, MW
Nittoli, T
Guo, LX
Sieburth, SM
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U205 - U205
[8] Histone deacetylase inhibitors.
Richon, VM
Breslow, R
Rifkind, RA
Marks, PA
CLINICAL CANCER RESEARCH, 2000, 6 : 4478S - 4478S
[9] DNA topoisomerases and their inhibitors.
Pommier, Y
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 25 - CARB
[10] Corrosion inhibitors. A review
Kadhim, A.
Al-Amiery, A. A.
Alazawi, R.
Al-Ghezi, M. K. S.
Abass, R. H.
INTERNATIONAL JOURNAL OF CORROSION AND SCALE INHIBITION, 2021, 10 (01): : 54 - 67

← 1 2 3 4 5 →